Success Stories: EB-1A Approved for Research Associate in California in the Field of Pharmaceutical Science
Client’s Testimonial:
Thank you very much for your help to get my I-140 approval. [...] I have already recommended your firm to many of my friends and I will continue to do so if I get the opportunity.
On January 14, 2015, We Received Another EB1-A (Alien of Extraordinary Ability) Approval for a Research Associate in the Field of Pharmaceutical Science (Approval Notice)
Position at the Time of Case Filing: Research Associate
Country of Origin: India
Country of Residence at the Time of Filing: California
Approval Notice Date: January 14th, 2015
Processing Time: 1 Year, 1 Months, 27 Days (Including RFE Response Time)
An Indian pharmaceutical scientist was our client in this case. His specialized research had focused on drug design. His body of work comprised 13 peer-reviewed scientific articles and numerous presentations at national and international conferences; by the time we filed his case, his research had received no fewer than 115 citations from independent and leading researchers at prestigious institutions and organizations around the world, a strong indication of the major significance of his work. He has also performed peer-review service for at least 5 distinctive, internationally-circulated journals, reviewing at least 25 manuscripts. An independent recommender attested to our client’s superior expertise: “His publications demonstrate great innovation and a discerning mind, and his extensive background in pharmaceutical science has proven to be a great asset in his field of endeavor. [Client] has made impressive contributions in anti-tuberculosis drug design to circumvent drug resistance, as well as the development of enzyme screening assays and exhaustively reviewing targets and inhibitors of mycobacteria.” It was our goal to prove that our client qualified for classification as an Alien of Extraordinary Ability given that he sought to remain in the United States to continue work in the area of Pharmaceutical Science, and that his continued research would substantially and prospectively benefit the United States. With the proof and documentation that we provided, his case was approved in one year, one month, and twenty-seven days.